Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

RCT (n=736) found that amongst patients in remission after 12 months of certolizumab, those who received ongoing full maintenance or reduced dose were more likely to be flare free after 1 further year vs placebo (83.7% and 79.0% vs 20.2%, p<0.001 for both placebo comparisons).


Annals of the Rheumatic Diseases